Condition (MeSH)
Soft Tissue Infections
ClinicalTrials.gov lists 83 trials for Soft Tissue Infections or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
83 of the 83 trials are tagged with Soft Tissue Infections itself; the rest are tagged with a narrower condition beneath it.
When did Soft Tissue Infections trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 1 |
| 2020 | 5 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Soft Tissue Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 3 | 13 |
| Phase 4 | 10 |
| Not applicable | 24 |
| Observational | 25 |
| Expanded access | 1 |
How many Soft Tissue Infections trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Enrolling by invitation | 2 |
| Completed | 57 |
| Terminated | 7 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Soft Tissue Infections trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 5 |
| GBR Academy | 3 |
| Inflammatix | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Paratek Pharmaceuticals Inc | 3 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Soft Tissue Infections? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Omadacycline | 3 |
| Aztreonam | 3 |
| Iclaprim | 2 |
| Delafloxacin | 2 |
| Ceftaroline Fosamil | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Vancomycin 1.1% | 8 |
| Daptomycin 6mg/kg/day | 4 |
| Zyvox - linezolid | 4 |
| Cephalexin suspension (Keflex) | 2 |
| 4% Chlorhexidine Gluconate | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Soft Tissue Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Readmission | 27 | 1 |
| SAEs | 23 | 1 |
| Cellulitis | 13 | 6 |
| Pneumonia | 13 | 9 |
| Progressive ischemia leading to necrosis and amputation | 11 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Soft Tissue Infections? (169)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Default Antibiotic Order Durations for Skin and Soft Tissue Infections in Outpatient Pediatrics: A Cluster Randomized Trial. | Journal of the Pediatric Infectious Diseases Society | 2025 | Yes |
| Blood from septic patients with necrotising soft tissue infection treated with hyperbaric oxygen reveal different gene expression patterns compared to standard treatment. | BMC medical genomics | 2025 | Yes |
| Improving Empiric Antibiotic Selection for Patients Hospitalized With Skin and Soft Tissue Infection: The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial. | JAMA internal medicine | 2025 | Yes |
| The safety and efficacy of a single dose of oral azithromycin given in labour to prevent skin and soft tissue infections in young infants in Fiji: a randomised controlled trial. | BMC medicine | 2025 | Yes |
| Real-time identification of life-threatening necrotizing soft-tissue infections using indocyanine green fluorescence imaging. | Journal of biomedical optics | 2024 | Yes |
Showing 5 of 169 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.